AEGIS' Touchstone Project to help providers implement FHIR

AEGIS.net, creator of the AEGIS Developers Integration Lab (DIL), has introduced the Touchstone Project, a next generation cloud-based testing platform that applies conformance and interoperability testing in a test-driven-development (TDD) integrated ecosystem. 

The Touchstone Test Platform will help organizations new to the HL7 Fast Healthcare Interoperability Resources (FHIR) specification begin to explore and evaluate it. 

AEGIS unveiled the Touchstone Project to a distinguished group of Health IT industry leaders at the HL7® International 29th Annual Plenary & Working Group Meetings in Atlanta last month.

After its initial month of FHIR Testing, Touchstone has seen more than 185 unique test executions and counting. Those organizations currently testing HL7 FHIR against the AEGIS Touchstone Test Platform are encouraged to publish their HL7 FHIR Conformance Testing results for the public to witness.

"Iterative testing remains at the heart of agile development," said Charles Jaffe, MD, PhD, CEO of HL7, in a release. "Valid conformance is critical to both the developers and to the end-user community. Iterative testing drives quality and patient safety, and supports innovation. A successful testing program also provides FHIR development teams at HL7 with the essential infrastructure that is critical for all of our stakeholders."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.